This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

SAMR discloses deal abandonments in pharma, natural-monopoly sectors in 2024

By MLex Staff ( February 28, 2025, 06:15 GMT | Insight) -- China’s top merger-control regulator revealed that its deal reviews in 2024 led to deal abandonments in key sectors such as pharmaceuticals and natural monopolies after it identified competition concerns. In its 2024 merger review wrap-up, the State Administration for Market Regulation disclosed on its website that deals in pharmaceuticals, natural monopolies and critical electronic materials faced heightened scrutiny.China’s top merger-control regulator has revealed that its deal reviews in 2024 led to deal abandonments in key sectors such as pharmaceuticals and natural monopolies after it identified competition concerns....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login